Welcome to Gaia! :: View User's Journal | Gaia Journals

Figure optionsDownload full-size imageDownload as PowerPoint slide
We then performed an invitro reporter assay with CES1A2 promoter with major and minor haplotypes in HepG2 cells. As shown in Fig. 1B, the promoter activity of the CES1A2-minor haplotype was significantly higher than that of the CES1A2-major haplotype (mean ± SE: 2.33 ± 0.08 vs. 0.81 ± 0.10; p MG 149 are detected by EMSA. Shifted complexes are marked with an arrow. (B) Cold-competition assay with unlabeled minor or major haplotype probes. (C) Supershift assay using an anti-Sp1 protein antibody and a control rabbit IgG.
Figure optionsDownload full-size imageDownload as PowerPoint slide
Discussion
The current study was undertaken to clarify the molecular mechanism by which a CES1A2 polymorphism ?816A/C associate with responder and non-responder of medication with a CES1-dependent ACE inhibitor [7]. We re-sequenced the CES1A2 promoter and found polymorphisms that collectively build two haplotypes: one with and another without putative Sp1 transcription factor binding sites. Transfection assay and EMSA showed that the Sp1 binding site in the promoter region is indeed functional. Since the ?816A/C was in high LD, we conclude that these Sp1 variant haplotypes are likely to be the functional SNPs of our previous observation.